Back to search

University of Birmingham

Design, synthesis and evaluation of mechanism-based inhibitors of IDO1 and PROTAC-degraders of JAK2

Abstract

dc:description.abstract

Over-expression of indolamine-2,3-dioxygenase 1 (IDO1) and programmed death-ligand 1 (PD-L1) are common phenotypes of immunoresistant cancers. The expression of IDO1 and PD-L1 is mediated by the janus kinase-signal transducer and activator of transcription (JAK-STAT) pathway in response to stimulation by interferon-gamma (IFN gamma), with tumoral signalling specifically transduced via JAK2. IDO1’s role in tumour immunoresistance is mediated by both depletion of its substrate, L-tryptophan, and by metabolites derived from its product, N-formyl-L-kynurenine. The mechanism of IDO1-mediated dioxygenation of L-tryptophan to N-formyl-L-kynurenine proceeds by either a radical or electrophilic-based mechanism. Radicals adjacent to cyclopropane rings undergo ring-opening driven by relief of ring strain, with the rate of ring-opening dependent on the stability of the resulting radical. A series of cyclopropane-containing IDO1 substrate mimics were designed to divert the hypothesised radical dioxygenation mechanism, potentially resulting in enzyme inhibition resulting from either a mechanistic ‘dead-end’ or covalent inactivation of the protein. Based on tryptophan and tryptamine, 1,2-cyclopropanated analogues were synthesised via a 1,3-dipolar cycloaddition of an amino acrylate and a indolo-diazo species or the Rh-catalysed cyclopropanation of a terminal olefin. Complimentary spirocyclic cyclopropane analogues of tryptophan and tryptamine were accessed via cyclodialkylation of 3-indoleacetonitrile. A library of sulfenylindoles was also synthesised to divert late-stage metabolic intermediates in a non-radical dependent manner. The synthesised inhibitors were exposed to IFN gamma-stimulated SCOV-3 cells and demonstrated a broadly poor ability to inhibit IDO1 turnover of tryptophan. Novel cell-free assays were developed to ascertain whether the reduced reactivity was related to compound cell-permeability and to further probe the mechanistic-detail of IDO1. A promising IDO1 inhibitor was identified in the cell-free assays and the further evaluation of the candidate is described. Study of JAK2’s role in tumour immune escape has been complicated by inhibitors direct effects on immune cells, which is thought to be mediated by inhibition of other JAK family members. Proteolysis targeting chimeras (PROTACs) have the ability to degrade proteins within cells by harnessing the ubiquitin-proteasomal system. Based on FDA-approved JAK2 ligand fedratinib, a series of PROTACs were synthesised. The synthesised PROTACs were evaluated in JAK2-expressing HeLa cells. Degradation of JAK2 in HeLa cells was not observed in the preliminary western-blot analysis – future investigations of JAK2 PROTACs is discussed.

Degree

thesis:*
Name dc:type.qualificationname
d_ph
Level dc:type.qualificationlevel
d_ph
Grantor dc:publisher.institution
University of Birmingham
Year dc:date.issued
2020

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Cundy, Nicholas John
ORCID person:identifier.orcid

Subjects

dc:subject × 1

Rights

Language dc:language.dcterms_iso639_2
eng

Identifiers

dc:identifier.*
Dc Identifier Grantnumber
Design, Synthesis and Evaluation of Mechanism-Bsed Inhibitors of IDO1
Design, Synthesis and Evaluation of JAK2 PROTACs

Chain of custody

source
Harvested from
University of Birmingham
Base URL
etheses.bham.ac.uk/cgi/oai2
Last updated
2026-11-19
Source record
OAI-PMH GetRecord
citation

Cundy, Nicholas John. Design, synthesis and evaluation of mechanism-based inhibitors of IDO1 and PROTAC-degraders of JAK2. d_ph thesis, University of Birmingham, 2020.